Table 2.
Coronavirus disease 2019 (COVID-19) disease characteristics
| SARS-CoV-2 infection (n = 200) | ||
|---|---|---|
| Patient management, n (%) | ||
| Ambulatory care | 195 (97.5) | |
| Hospital admission to ward | 5 (2.5) | |
| Hospital admission to ICU | 0 | |
| Perceived severity, n (%) | ||
| Asymptomatic | 1 (0.5) | |
| Mild | 73 (36.5) | |
| Moderate | 102 (51.0) | |
| Severe | 22 (11.0) | |
| Very severe | 2 (1.0) | |
| Impact on daily life, n (%)a | ||
| 1 (no or mild impact) | 28 (14.0) | |
| 2 | 19 (9.5) | |
| 3 (moderate impact) | 80 (40.0) | |
| 4 | 48 (24.0) | |
| 5 (very important impact) | 25 (12.5) | |
| Reported symptoms | ||
| Median number of symptoms (IQR) | 9 (6–11) | |
| Median symptom density score (IQR), symptom-daysb | 36 (19–58) | |
| Symptoms | Frequency, n (%) | Median durations, days (IQR) |
| Acute | ||
| Myalgia | 147 (73.5) | 5 (3–8) |
| Headache | 142 (71.0) | 6 (3–10) |
| Cough | 126 (63.0) | 10 (4–17) |
| Fever | 123 (61.5) | 3 (2–6) |
| Nasal discharge | 110 (55.0) | 7 (3–10) |
| Chills | 107 (53.5) | 3 (1–4) |
| Dyspnoea | 87 (43.5) | 7 (4–15) |
| Diarrhoea | 76 (38.0) | 2 (1–5) |
| Arthralgia | 75 (37.5) | 5 (3–10) |
| Thoracic pain | 56 (28.0) | 6 (3–10) |
| Nausea | 50 (25.0) | 4 (2–6) |
| Dysphagia | 45 (22.5) | 5 (2–8) |
| Abdominal pain | 40 (20.0) | 3 (2–6) |
| Rash | 22 (11.0) | 6 (2–14) |
| Vomiting | 12 (6.0) | 2 (1–4) |
| Subacute | ||
| Fatigue | 174 (87.0) | 15 (8–21) |
| Anosmia | 138 (69.0) | 19 (10–38) |
| Dysgeusia | 133 (66.5) | 14 (7–30) |
| Others | Frequency, n (%) | Kgs, median (IQR) |
| Weight loss | 81 (40.5) | 3 (2–4) |
| Mean viral load, SD (log10 copies/mL) | 6.8 ± 1.7 | |
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ICU, intensive care unit; IQR, interquartile range.
a
Impact on daily life was assessed using scales with values in the range 1–5.
b
Symptom density score is the product of the total number of acute symptoms and the total duration (days) of each symptom.